<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of psoriasis in pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of psoriasis in pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of psoriasis in pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Miriam Keltz Pomeranz, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce E Strober, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Wilkins-Haug, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Psoriasis is a chronic skin disorder characterized by well-demarcated erythematous papules and plaques with a silver scale, although atypical or nonclassic forms also exist. It commonly occurs on the extensor surface of the elbows or knees, or the scalp  (<a class="graphic graphic_picture graphicRef54581 graphicRef87441 graphicRef87443" href="/z/d/graphic/54581.html" rel="external">picture 1A-C</a>). Psoriasis commonly occurs in individuals of reproductive age because three-quarters of patients develop the disease before reaching age 40 years [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>The management of psoriasis in pregnant patients will be reviewed here. The general treatment of psoriasis and pustular psoriasis of pregnancy, a severe pustular form of psoriasis, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SPECIAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>The presence of psoriasis in a woman who is pregnant raises unique considerations. Examples include the impact of maternal psoriasis on the fetus, therapeutic restrictions during pregnancy, and the effects of pregnancy on psoriasis severity [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of psoriasis on pregnancy outcomes </strong>– Few studies have investigated the impact of psoriasis on pregnancy outcomes, leaving the relationship between psoriasis and pregnancy outcomes unclear [<a href="#rid3">3,4</a>]. A 2016 systematic review of observational studies that evaluated the relationship between psoriasis and pregnancy outcomes found that four of the nine included studies reported increased risk for at least one adverse fetal outcome (spontaneous abortion, caesarean delivery, low birth weight, macrosomia, large-for-gestational age, or a composite outcome that included prematurity and low birth weight) [<a href="#rid3">3</a>]. However, study results were inconsistent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of pregnancy on treatment choices </strong>–<strong> </strong>Choosing drug therapies that pose the least risk to the fetus is the major issue in managing the pregnancies of affected patients. Ideally, patients should try to plan pregnancy when they are in remission and they are off medication or are taking the minimum effective dose of medications that have the best fetal safety profiles. Because many patients with moderate to severe psoriasis do not achieve complete remissions, postponing pregnancy until a period of remission is often unrealistic in this population. The selection of treatments with good fetal safety profiles is particularly important for these patients. (See <a class="local">'Treatment principles'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on severity of psoriasis </strong>–<strong> </strong>Psoriasis improves during pregnancy in 40 to 60 percent of patients, worsens in 10 to 20 percent, and remains stable in the remainder. Improvement may be dramatic. In a prospective study, among 16 women with greater than 10 percent body surface area involvement with psoriasis who experienced improvement in psoriasis during pregnancy, the mean reduction in psoriatic lesions between 10 and 30 weeks gestation was 84 percent [<a href="#rid5">5</a>]. In the postpartum period, psoriasis severity remains the same or worsens in most patients [<a href="#rid5">5-7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact on risk of psoriasis in biologic children </strong>– Children of individuals with psoriasis have an increased risk for the development of the disorder. (See  <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Genetic factors'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">TREATMENT PRINCIPLES</span><span class="headingEndMark"> — </span>Treatment of psoriasis in nonpregnant individuals can be divided into three broad categories: topical therapy, phototherapy, and systemic therapy. Choice of therapy is based upon the severity of the disease and its impact on the patient's overall sense of well-being, relevant comorbidities, patient preference (including cost and convenience), efficacy, and evaluation of individual patient response. Psoriasis involving limited areas of skin (eg, less than 5 to 10 percent the body surface area) can often be managed topically. Phototherapy or systemic therapy is usually necessary for adequate treatment of more extensive disease. Topical therapy and phototherapy is generally preferred over systemic therapy for the treatment of pregnant patients because of concern for safety. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p>The treatment paradigm is the same for both pregnant and nonpregnant patients, except that some medications are avoided in pregnancy and the risk/benefit ratio may be calculated differently because fetal risk must also be taken into account [<a href="#rid8">8</a>]. We agree with a recommendation from the Medical Board of the National Psoriasis Foundation that topical treatment with emollients or moisturizers and a low- or medium-potency topical corticosteroid is the first-line medical intervention for pregnant patients with limited psoriasis [<a href="#rid9">9</a>]. Ultraviolet B (UVB) phototherapy (particularly narrowband ultraviolet B [NBUVB]) is the preferred treatment for pregnant patients with more severe symptoms.</p><p>When patients receiving systemic therapy for psoriasis become pregnant, the decision must be made whether to continue treatment or to transition to topical therapy or phototherapy. Although contraindicated therapies (eg, <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>) must be discontinued, the appropriate action is less definitive for patients receiving other systemic treatments. Because many patients with psoriasis improve during pregnancy, patients may be able to switch to phototherapy during the prenatal period. Biologic tumor necrosis factor (TNF) inhibitors and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> are occasionally used during pregnancy for patients with severe disease who cannot transition to topical therapy or phototherapy. In these situations, the potential risks and benefits of therapy must be considered carefully. (See <a class="local">'Third-line therapy'</a> below and <a class="local">'Contraindicated therapies'</a> below.) </p><p>Treatment of nonpregnant individuals is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7793.html" rel="external">"Treatment of psoriatic arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/15279.html" rel="external">"Treatment selection for moderate to severe plaque psoriasis in special populations"</a>.)</p><p class="headingAnchor" id="H464711532"><span class="h2">First-line therapy</span><span class="headingEndMark"> — </span>Many pregnant patients with limited psoriasis (nondebilitating psoriasis that involves less than 5 to 10 percent of the body surface area) can be managed sufficiently with topical therapy. Emollients, moisturizers, and low- to medium-potency topical corticosteroids are the preferred topical therapies for this population based upon safety considerations  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H464711513"><span class="h3">Emollients and moisturizers</span><span class="headingEndMark"> — </span>The simplest topical therapies are emollients or moisturizers, which may control bothersome scale. Use of these agents is well tolerated, lacking significant adverse effects.</p><p class="headingAnchor" id="H5"><span class="h3">Topical corticosteroids</span><span class="headingEndMark"> — </span>For limited psoriasis, intermittent topical corticosteroids may control disease with no or minimal maternal or fetal risk [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Corticosteroids'</a>.)</p><p>A systematic review did not find sufficient evidence to link topical corticosteroid use to increased risk for congenital abnormalities, preterm delivery, or stillbirth [<a href="#rid12">12</a>]. However, there may be an association between use of potent topical corticosteroids and low birthweight [<a href="#rid12">12</a>]. In particular, a retrospective study found a correlation between low birth weight and high levels of potent or very potent topical corticosteroid use [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Use during pregnancy or lactation'</a>.)</p><p>Therefore, for pregnant patients who will be treated with topical corticosteroids for psoriasis, the use of low- or medium-potency topical corticosteroids is preferred  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>) [<a href="#rid9">9</a>]. We reserve the use of high-potency topical corticosteroids for patients who fail treatment with lower-potency topical corticosteroids.</p><p>Of note, the development of striae (stretch marks) is common in pregnancy and use of topical corticosteroids may increase risk for striae in sites of application. (See  <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">"Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'</a>.) </p><p class="headingAnchor" id="H464711787"><span class="h2">Second-line therapy</span><span class="headingEndMark"> — </span>When topical therapy with emollients, moisturizers, or topical corticosteroids is insufficient or impractical due to resistant disease or extensive skin involvement, NBUVB phototherapy is often useful for treatment.</p><p class="headingAnchor" id="H10"><span class="h3">Ultraviolet B phototherapy</span><span class="headingEndMark"> — </span>Phototherapy can be used to treat localized psoriasis or the entire cutaneous surface area. NBUVB phototherapy at wavelength 311 nm appears to be a safe and often effective treatment of psoriasis in pregnant patients [<a href="#rid10">10,11</a>]. The major disadvantage of this approach is the need to travel to a clinic three days per week for treatment. Broadband UVB (290 to 320 nm) is a slightly less effective alternative that can be used if NBUVB is not available. Localized disease can be treated with a laser device that emits UVB (eg, 308 nm excimer laser) [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.)</p><p>Patients receiving phototherapy generally require adjuvant therapy with emollients, moisturizers, or low- to medium-potency topical corticosteroids for symptomatic relief.</p><p>Common adverse effects of UVB phototherapy include erythema, skin dryness, and pruritus. Exacerbation of melasma, a photosensitive skin disorder commonly associated with pregnancy, also is a potential risk of phototherapy [<a href="#rid9">9</a>]. Melasma is characterized by the development of hyperpigmentation on sun-exposed skin  (<a class="graphic graphic_picture graphicRef64109" href="/z/d/graphic/64109.html" rel="external">picture 2</a>) (see  <a class="medical medical_review" href="/z/d/html/6621.html" rel="external">"Melasma: Management"</a>). To minimize risk of melasma, shielding of the face during phototherapy is advised [<a href="#rid2">2</a>]. Additional adverse effects associated with phototherapy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)", section on 'Short- and long-term adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Adverse effects'</a>.)</p><p>Maternal folate deficiency has been associated with an increased risk for fetal neural tube defects. Concerns regarding the effect of ultraviolet light exposure decreasing serum folate levels are discussed separately.</p><p class="headingAnchor" id="H464712024"><span class="h2">Third-line therapy</span><span class="headingEndMark"> — </span>Most pregnant patients with psoriasis can be managed effectively with the therapies described above. Patients who cannot be managed effectively with the topical moisturizers, topical corticosteroids, or phototherapy may require systemic therapy to achieve sufficient improvement in symptoms. Biologic TNF inhibitors and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> can be effective for these patients. However, data on safety in pregnant individuals are limited, and the need for systemic treatment should be considered carefully.</p><p class="headingAnchor" id="H464712088"><span class="h3">Anti-tumor necrosis factor biologic agents</span><span class="headingEndMark"> — </span>Although data on the use of anti-tumor necrosis factor (TNF) biologic agents in pregnancy are limited, there is a growing body of literature demonstrating that the biologic TNF inhibitors used for psoriasis may be used safely during pregnancy. Increased risk for preterm birth and small for gestational age infants have been reported, but effects of underlying, inflammatory diseases are also postulated to contribute [<a href="#rid14">14,15</a>].</p><p>Transfer of <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>, a pegylated, Fc-free anti-TNF biologic agent used for psoriasis, across the placenta is minimal and less than other anti-TNF biologic agents. Limited data support low risk for immunosuppression in the newborn and teratogenicity for this agent [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p>Because <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> can cross the placenta and can be detected in infants for up to several months or longer after birth [<a href="#rid18">18,19</a>], there is concern for the possibility of postpartum effects on infants born to treated individuals. Although the best approach is unconfirmed, discontinuation of these drugs prior to the end of gestation and postponement of live vaccine administration to infants has been suggested. For infliximab, drug discontinuation is suggested at 30 weeks gestation (based upon the knowledge that transmission across the placenta primarily occurs in the third trimester), and avoidance of live vaccine administration to infants born to treated individuals is suggested until the age of seven months [<a href="#rid20">20,21</a>]. Similar precautions may be appropriate for adalimumab and etanercept. An infant exposed to infliximab in utero died from disseminated Bacillus Calmette-Guérin (BCG) infection after receipt of the <a class="drug drug_general" data-topicid="102736" href="/z/d/drug information/102736.html" rel="external">BCG vaccine</a> at the age of three months [<a href="#rid22">22</a>].</p><p>The manufacturers of all the biologic medications for psoriasis and psoriatic arthritis manage ongoing registries of drug-exposed pregnant patients and encourage enrollment of all such cases. The safety of these drugs in pregnant individuals is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Tumor necrosis factor inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease", section on 'Anti-tumor necrosis factor agents'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">Cyclosporine</a> is a calcineurin inhibitor.</p><p>Teratogenicity data in humans are derived primarily from organ transplant recipients. The risk of teratogenicity among the offspring of women treated with <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> appears to be low, but premature labor and infants who are small for gestational age have been reported. Such findings may be related to the underlying medical condition rather than to the drug and could also be related to both the medical condition and the drug. Another concern is that, in some studies, newborns whose mothers consumed cyclosporine had a decrease in T and B cells [<a href="#rid11">11</a>]; however, it is not clear that this change had any clinical significance. The use of cyclosporine in pregnancy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Cyclosporine'</a>.)</p><p class="headingAnchor" id="H464711110"><span class="h1">CONTRAINDICATED THERAPIES</span><span class="headingEndMark"> — </span>Several therapies useful for the treatment of psoriasis in nonpregnant individuals are contraindicated in pregnant patients because of teratogenicity. These include topical <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a>.</p><p class="headingAnchor" id="H464711171"><span class="h2">Tazarotene</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">Tazarotene</a> is a retinoid approved for the topical treatment of psoriasis. Tazarotene is contraindicated in pregnancy [<a href="#rid23">23,24</a>].</p><p>Less than 1 percent of the dose is absorbed on psoriatic skin [<a href="#rid25">25</a>]. However, <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a> is avoided during pregnancy based on good data that another retinoid (oral <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>) is associated with a significant increase in major congenital malformations. First trimester oral isotretinoin exposure is strongly associated with embryopathy, including craniofacial, cardiac, thymic, and central nervous system malformations. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Tazarotene'</a> and  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Teratogenicity'</a>.)</p><p class="headingAnchor" id="H464711334"><span class="h2">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> is a folate antagonist and is contraindicated in pregnancy. It should <strong>not</strong> be used for treatment of psoriasis in a pregnant or lactating woman because it is teratogenic and may interfere with cellular metabolism in a nursing infant [<a href="#rid24">24</a>]. Conception should be avoided for three months after the last dose because the drug can persist in the liver for several months. This drug is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Methotrexate'</a>.)</p><p class="headingAnchor" id="H464711340"><span class="h2">Acitretin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> is contraindicated in pregnancy, given that there is good evidence that retinoids significantly increase the incidence of severe congenital anomalies in experimental animals and humans [<a href="#rid26">26</a>]. It should <strong>not</strong> be used for treatment of psoriasis in a pregnant or lactating woman. (See  <a class="medical medical_review" href="/z/d/html/38.html" rel="external">"Oral isotretinoin therapy for acne vulgaris", section on 'Teratogenicity'</a>.)</p><p><a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">Acitretin</a> can be metabolized to etretinate in the body, and etretinate has been identified in body fat as long as 52 months after stopping acitretin [<a href="#rid27">27</a>]. For this reason, experts recommend that pregnancy be avoided for three years after the last dose of acitretin.</p><p class="headingAnchor" id="H464711538"><span class="h1">OTHER PSORIASIS THERAPIES</span><span class="headingEndMark"> — </span>Several other psoriasis therapies, while not deemed contraindicated for patients with psoriasis, are less favorable options for the treatment of pregnant patients due to safety concerns or lesser efficacy.</p><p class="headingAnchor" id="H464712240"><span class="h2">Topical calcineurin inhibitors</span><span class="headingEndMark"> — </span>Topical calcineurin inhibitors (eg, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">pimecrolimus</a>) are not particularly effective in psoriasis; however, they are occasionally used when topical corticosteroids must be avoided. </p><p>Based on experimental animal studies and human case reports, these drugs do not appear to increase the risk of congenital anomalies. Treatment with<strong> oral</strong> <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> may be associated with increased risk for low birth weight and premature delivery [<a href="#rid9">9</a>]. However, it is unclear whether similar effects occur with the low systemic absorption associated with topical administration. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation"</a>.)</p><p class="headingAnchor" id="H464711927"><span class="h2">Coal tar</span><span class="headingEndMark"> — </span>Safety data for <a class="drug drug_general" data-topicid="8878" href="/z/d/drug information/8878.html" rel="external">coal tar</a> in pregnancy are limited. Although there is concern for potential mutagenic properties of coal tar based upon animal studies, a case series including 23 women who used coal tar products during pregnancy did not detect an increase in congenital anomalies [<a href="#rid28">28</a>]. Topical coal tar can be considered for use in the second and third trimesters of pregnancy [<a href="#rid10">10,11</a>]. As a precaution, coal tar is often avoided in the first trimester of pregnancy. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults"</a>.)</p><p class="headingAnchor" id="H464711640"><span class="h2">Calcipotriol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9181" href="/z/d/drug information/9181.html" rel="external">Calcipotriol</a> (calcipotriene) and <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">calcitriol</a> are vitamin D derivatives. Studies in rats and rabbits have not reported an increased risk of congenital anomalies [<a href="#rid26">26</a>]. Hypercalcemia has been reported with excessive topical use [<a href="#rid29">29</a>], and excessive vitamin D intake can lead to skeletal abnormalities in offspring [<a href="#rid26">26</a>]; however, this is unlikely with limited topical use [<a href="#rid11">11,23,24</a>]. (See  <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">"Treatment of psoriasis in adults", section on 'Topical vitamin D analogs'</a>.)</p><p class="headingAnchor" id="H464713798"><span class="h2">Anthralin</span><span class="headingEndMark"> — </span>The risks of <a class="drug drug_general" data-topicid="8814" href="/z/d/drug information/8814.html" rel="external">anthralin</a> therapy during pregnancy are unknown. Therefore, use of anthralin in pregnant patients is not recommended [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H464712962"><span class="h2">Psoralen plus ultraviolet A phototherapy</span><span class="headingEndMark"> — </span>Use of systemic psoralen plus ultraviolet A (PUVA) phototherapy during pregnancy is more controversial than use of ultraviolet B (UVB) phototherapy. Some experts suggest it can be used if the psoralen is applied topically [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p class="headingAnchor" id="H464713122"><span class="h2">Sulfasalazine</span><span class="headingEndMark"> — </span>Case series have found no increase in the incidence of adverse pregnancy outcomes with <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> exposure during pregnancy. Since sulfasalazine binds albumin, there is a theoretic risk that sulfasalazine will displace bilirubin from albumin and thereby increase the risk of kernicterus; however, there is no evidence that clinically significant displacement of bilirubin occurs. Although the safety profile of sulfasalazine is reassuring, it is minimally effective for treatment of psoriasis. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Sulfasalazine'</a>.)</p><p class="headingAnchor" id="H464713457"><span class="h2">Systemic glucocorticoids</span><span class="headingEndMark"> — </span>Systemic glucocorticoids are not recommended for the treatment of psoriasis because of the potential for severe flaring of psoriasis upon drug withdrawal. An exception is pustular psoriasis of pregnancy (impetigo herpetiformis), for which systemic glucocorticoids are a mainstay of therapy. (See  <a class="medical medical_review" href="/z/d/html/5564.html" rel="external">"Dermatoses of pregnancy", section on 'Pustular psoriasis of pregnancy'</a>.)</p><p class="headingAnchor" id="H464712361"><span class="h2">Ustekinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> is a monoclonal antibody that targets interleukin (IL) 12 and IL-23. Data on the safety of ustekinumab in pregnancy are primarily limited to animal studies. Individual cases of uncomplicated delivery of a healthy infant [<a href="#rid30">30-34</a>] and spontaneous abortion [<a href="#rid35">35</a>] have been reported in patients treated with ustekinumab during pregnancy. Pending further study, anti-tumor necrosis factor (TNF) biologic therapy is preferred over ustekinumab for psoriasis in the pregnant population.</p><p class="headingAnchor" id="H1031454269"><span class="h2">Other biologic agents and apremilast</span><span class="headingEndMark"> — </span>There are insufficient data regarding fetal exposure to <a class="drug drug_general" data-topicid="107448" href="/z/d/drug information/107448.html" rel="external">ixekizumab</a>, <a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">secukinumab</a>, and <a class="drug drug_general" data-topicid="112051" href="/z/d/drug information/112051.html" rel="external">brodalumab</a>, newer IL-17 inhibitors approved for the treatment of moderate to severe psoriasis. An analysis of the manufacturer's global safety database for secukinumab through June 2017 identified no safety signals with regard to spontaneous abortions or congenital malformations [<a href="#rid36">36</a>].</p><p>There are insufficient data regarding the IL-23 inhibitors <a class="drug drug_general" data-topicid="114007" href="/z/d/drug information/114007.html" rel="external">guselkumab</a>, <a class="drug drug_general" data-topicid="117344" href="/z/d/drug information/117344.html" rel="external">tildrakizumab</a>, and <a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a>. Similarly, there are insufficient data regarding <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a>, an oral phosphodiesterase type 4 inhibitor. A moderate level of caution should be employed with use of these medications in the setting of pregnancy.</p><p class="headingAnchor" id="H268489372"><span class="h2">Fumaric acid</span><span class="headingEndMark"> — </span>Fumaric acid esters are used to treat psoriasis in Europe. Although animal studies do not show any teratogenicity, there are very limited data in humans. Therefore, the use of fumaric acid esters is not recommended in a pregnant woman [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H1464530986"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112498.html" rel="external">"Society guideline links: Psoriasis"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– The effect of maternal psoriasis on pregnancy outcomes remains uncertain. Choosing drug therapies that pose the least risk to the fetus is the major issue in managing the pregnancies of affected patients. (See <a class="local">'Special considerations'</a> above and <a class="local">'Treatment principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of pregnancy </strong>– Ideally, patients should plan pregnancy when they are in remission and off medication or taking the minimum effective dose of medications that have the best fetal safety profiles. However, postponing pregnancy until a period of remission is often unrealistic. The selection of treatments with good fetal safety profiles is particularly important for these patients. (See <a class="local">'Special considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of pregnancy on psoriasis </strong>– Psoriasis improves during pregnancy in 40 to 60 percent of patients, worsens in 10 to 20 percent, and remains stable in the remainder. In patients who improve, the degree of improvement can be dramatic. In the postpartum period, psoriasis severity remains the same or worsens in most patients. (See <a class="local">'Special considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with limited psoriasis </strong>– For pregnant patients with limited psoriasis (ie, nondebilitating psoriasis that involves less than 5 to 10 percent of the body surface area), we suggest topical rather than systemic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Emollients and moisturizers are useful for reducing bothersome scale. Our first-line medical treatment is a low- to medium-potency topical corticosteroid  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 1</a>). (See <a class="local">'First-line therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with topical therapy-resistant or extensive psoriasis </strong>– For patients with psoriasis that cannot be managed adequately with topical therapy (ie, resistant or extensive disease), we suggest narrowband ultraviolet B (NBUVB) phototherapy rather than systemic therapies because of the safety and efficacy of phototherapy in pregnancy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Because psoriasis often improves during pregnancy, patients who required systemic treatment prior to pregnancy may be able to transition to phototherapy. (See <a class="local">'Ultraviolet B phototherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindicated therapies </strong>– Topical <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">tazarotene</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9250" href="/z/d/drug information/9250.html" rel="external">acitretin</a> are <strong>contraindicated</strong> during pregnancy. (See <a class="local">'Contraindicated therapies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barker JN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001; 26:321.</a></li><li><a class="nounderline abstract_t">Gottlieb AB, Ryan C, Murase JE. Clinical considerations for the management of psoriasis in women. Int J Womens Dermatol 2019; 5:141.</a></li><li><a class="nounderline abstract_t">Bobotsis R, Gulliver WP, Monaghan K, et al. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol 2016; 175:464.</a></li><li><a class="nounderline abstract_t">Bröms G, Haerskjold A, Granath F, et al. Effect of Maternal Psoriasis on Pregnancy and Birth Outcomes: A Population-based Cohort Study from Denmark and Sweden. Acta Derm Venereol 2018; 98:728.</a></li><li><a class="nounderline abstract_t">Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005; 141:601.</a></li><li><a class="nounderline abstract_t">Dunna SF, Finlay AY. Psoriasis: improvement during and worsening after pregnancy. Br J Dermatol 1989; 120:584.</a></li><li><a class="nounderline abstract_t">Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 1996; 35:169.</a></li><li><a class="nounderline abstract_t">Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59:295.</a></li><li><a class="nounderline abstract_t">Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2012; 67:459.</a></li><li><a class="nounderline abstract_t">Weatherhead S, Robson SC, Reynolds NJ. Management of psoriasis in pregnancy. BMJ 2007; 334:1218.</a></li><li><a class="nounderline abstract_t">Tauscher AE, Fleischer AB Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg 2002; 6:561.</a></li><li><a class="nounderline abstract_t">Chi CC, Lee CW, Wojnarowska F, Kirtschig G. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev 2009; :CD007346.</a></li><li><a class="nounderline abstract_t">Chi CC, Wang SH, Mayon-White R, Wojnarowska F. Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study. JAMA Dermatol 2013; 149:1274.</a></li><li><a class="nounderline abstract_t">Bröms G, Kieler H, Ekbom A, et al. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf 2020; 29:316.</a></li><li><a class="nounderline abstract_t">Tsao NW, Rebic N, Lynd LD, De Vera MA. Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2020; 59:1808.</a></li><li><a class="nounderline abstract_t">Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol 2018; 70:1399.</a></li><li><a class="nounderline abstract_t">Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77:228.</a></li><li><a class="nounderline abstract_t">Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:286.</a></li><li><a class="nounderline abstract_t">Labetoulle R, Roblin X, Paul S. Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy. Ann Intern Med 2018; 169:60.</a></li><li><a class="nounderline abstract_t">Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014; 70:401.e1.</a></li><li><a class="nounderline abstract_t">Heller MM, Wu JJ, Murase JE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol 2011; 65:870.</a></li><li><a class="nounderline abstract_t">Cheent K, Nolan J, Shariq S, et al. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4:603.</a></li><li><a class="nounderline abstract_t">Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin 2006; 24:167.</a></li><li class="breakAll">Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 7th ed, Williams and Wilkins, 2005.</li><li><a class="nounderline abstract_t">Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000; 43:S31.</a></li><li class="breakAll">www.reprotox.org (Accessed on December 18, 2007).</li><li><a class="nounderline abstract_t">Maier H, Hönigsmann H. Concentration of etretinate in plasma and subcutaneous fat after long-term acitretin. Lancet 1996; 348:1107.</a></li><li><a class="nounderline abstract_t">Franssen ME, van der Wilt GJ, de Jong PC, et al. A retrospective study of the teratogenicity of dermatological coal tar products. Acta Derm Venereol 1999; 79:390.</a></li><li><a class="nounderline abstract_t">Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994; 235:281.</a></li><li><a class="nounderline abstract_t">Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012; 11:1240.</a></li><li><a class="nounderline abstract_t">Sheeran C, Nicolopoulos J. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol 2014; 55:235.</a></li><li><a class="nounderline abstract_t">Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol 2016; 30:488.</a></li><li><a class="nounderline abstract_t">Rocha K, Piccinin MC, Kalache LF, et al. Pregnancy during Ustekinumab Treatment for Severe Psoriasis. Dermatology 2015; 231:103.</a></li><li><a class="nounderline abstract_t">Galli-Novak E, Mook SC, Büning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol 2016; 30:e191.</a></li><li><a class="nounderline abstract_t">Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 2012; 6:105.</a></li><li><a class="nounderline abstract_t">Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol 2018; 179:1205.</a></li><li><a class="nounderline abstract_t">Yiu ZZ, Warren RB, Mrowietz U, Griffiths CE. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat 2015; 26:329.</a></li></ol></div><div id="topicVersionRevision">Topic 5663 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11422183" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Genetic aspects of psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31360745" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical considerations for the management of psoriasis in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991866" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29542809" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of Maternal Psoriasis on Pregnancy and Birth Outcomes: A Population-based Cohort Study from Denmark and Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897382" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hormonal effect on psoriasis in pregnancy and post partum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2730848" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Psoriasis: improvement during and worsening after pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8655230" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psoriasis and pregnancy: hormone and immune system interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18410980" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018758" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556479" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of psoriasis in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12362257" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Psoriasis and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588425" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Safety of topical corticosteroids in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005903" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pregnancy outcomes after maternal exposure to topical corticosteroids: a UK population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32020767" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32118278" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29623679" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29030361" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23200982" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507939" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prolonged Persistence of Adalimumab Transferred From Mother to Infant During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24528911" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21920245" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21122568" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677965" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The use of dermatologic drugs in pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677965" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The use of dermatologic drugs in pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898827" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pharmacokinetics and safety of tazarotene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10898827" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacokinetics and safety of tazarotene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874484" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Concentration of etretinate in plasma and subcutaneous fat after long-term acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10494722" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A retrospective study of the teratogenicity of dermatological coal tar products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120527" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hypercalcaemic crisis after excessive topical use of a vitamin D derivative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23134993" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Treatment of severe psoriasis with ustekinumab during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25117169" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25413895" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25790947" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pregnancy during Ustekinumab Treatment for Severe Psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26559393" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23329988" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Spontaneous abortion during ustekinumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29927479" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25424052" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
